fbpx Pius Maliakal - Plus Therapeutics (PSTV)

Team Member

Pius Maliakal, PhD

Vice President, Clinical Operations

Pius Maliakal, M. Pharm., Ph.D. is the Vice President of Clinical Operations at Plus Therapeutics, Inc. and is responsible for the strategy and planning of key clinical operational initiatives, focusing on advancing the Company’s lead clinical trials, ReSPECT-GBM and ReSPECT-LM, and further developing the broader pipeline.

Dr. Maliakal is an accomplished R&D professional who brings over 20 years of global and domestic experience to Plus Therapeutics. Prior to joining the Company, he served as Director of Clinical Science at PTC Therapeutics, leading the clinical development, clinical trial operations, strategies, and data interpretations of all oncology assets across the enterprise. Previously, as Director of Clinical Development at Eagle Therapeutics, he led and facilitated the core design and conduct of Phase 1 and 2 clinical trials within breast cancer, lung cancer and other solid tumors. During his prior tenure at Immunomedics, he was instrumental in the Phase 1 through Phase 3 clinical trials of Trodelvy (sacituzumab govitecan) leading to accelerated FDA approval for treatment of triple-negative breast cancer as well as other investigational agents, including unesbulin and emvododstat.

Dr. Maliakal earned his M. Pharm. from Nagpur University, India and his Ph.D. from the University of Otago, New Zealand.